Attenuation of cytogenetic effects by erythropoietin in human lymphocytes in vitro and P388 ascites tumor cells in vivo treated with irinotecan (CPT-11)

Food and Chemical Toxicology

Volumn 48, Issue 1, 2010, Pages 242-249

  Digkas, E ^a   Kareli, D ^a   Chrisafi, S ^a   Passadaki, T ^a   Mantadakis, E ^a   Hatzimichail, A ^a   Vargemezis, V ^a   Lialiaris, Th ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Erythropoietin; Genotoxicity; Irinotecan; Lymphocytes; P388 ascites tumor cells; Sister chromatid exchanges (SCEs)

Indexed keywords

IRINOTECAN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANIMAL EXPERIMENT; ARTICLE; ASCITES TUMOR CELL; CELL PROTECTION; CONTROLLED STUDY; CYTOGENETICS; CYTOSTASIS; DRUG CYTOTOXICITY; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMIA P 388; LYMPHOCYTE; MALE; MITOSIS INDEX; MITOSIS RATE; MOUSE; NONHUMAN; SISTER CHROMATID EXCHANGE;

ADOLESCENT; ADULT; ANIMALS; ANTIMUTAGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL PROLIFERATION; CELLS, CULTURED; ERYTHROPOIETIN, RECOMBINANT; HUMANS; LEUKEMIA P388; LYMPHOCYTES; MICE; MITOSIS; MUTAGENS; SISTER CHROMATID EXCHANGE; YOUNG ADULT;

LONCHOCARPUS GLAUCIFOLIUS; MUS;

EID: 72149103536     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2009.10.007     Document Type: Article

References (52)

1. Allen J.N., Schuler C.F., Mendes R.W., and Latt S.A. A simplified technique for in vivo analysis of sister-chromatid exchanges using 5-bromodeoxyuridin tablets. Cytogenet. Cell Genet. 18 4 (1977) 231-237
2. Arsenou E., Fousteris M., Koutsurea A., Papageorgiou A., Karayianni V., Mioglou E., Iakovidou Z., Mourelatos D., and Nikolaropoulos S.S. The allylic 7-ketone at the steroidal skeleton is crucial for the antileukemic potency of chlorambucils active metabolite steroidal esters. Anticancer Drugs 15 (2004) 983-990
3. Buemi M., Caccano C., Nostro L., Cavallaro E., Floccari F., and Grasso G. Brain and cancer: the protective role of erythropoietin. Med. Res. Rev. 25 2 (2005) 245-249
4. Chaterjee A., Digumarti R., Mamidi S., Katneni K., Upreti V.V., Surath A., Srinivas M.L., Uppalapati S., Jiwatani S., and Srinivas N.R. Safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation study. J. Clin. Pharmacol. 44 (2004) 723-736
5. Csete M., Rodriguez L., Wilcox M., and Chadalavada S. Erythropoietin receptor is expressed on adult rat dopaminergic neurons and erythropoietin is neurotrophic in cultured dopaminergic neuroblasts. Neurosci. Lett. 359 (2004) 124-126
6. Damen J., Mui A., Hughes P., Humphries K., and Krystal G. Erythropoietin-induced tyrosine phosphorylations in a high erythropoietin receptor-expressing lymphoid cell line. Blood 80 8 (1992) 1923-1932
7. Daza P., Torreblanca J., García-Herdugo G., and Moreno F.J. DNA-strand breaks induced by the topoisomerase I inhibitor camptothecin in unstimulated human white blood cells. Cell Biol. Int. 26 8 (2002) 707-713
8. Dodds H.M., Haaz M.C., Riou J.F., Robert J., and Rivory L.P. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. J. Pharmacol. Exp. Ther. 286 1 (1998) 578-583
9. Farrell F., and Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9 (2004) 18-30
10. Genc K., Genc S., Baskin H., and Semin I. Erythropoietin decreases cytotoxicity and nitric oxide formation induced by inflammatory stimuli in rat oligodendrocytes. Physiol. Res. 55 (2006) 33-38
11. Imamura M., Han M., Hashino S., Kobayashi H., Imai K., Kobayashi S., Tanaka J., Zhu X., Kobayashi M., Fujii Y., Kasai M., Sakurada K., and Miyazaki T. In vivo effects of the immunosuppressant 15-deoxyspergualin on hematopoiesis in murine allogeneic bone marrow chimeras. Transplantation 58 2 (1994) 214-223
12. Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur. J. Haematol. 69 (2002) 265-274
13. Karayianni V., Papageorgiou A., Mioglou A., Iakovidou Z., Mourelatos D., Fousteris M., Koutsourea A., Arsenou E., and Nikolaropoulos S. 7-Keto hybrid steroidal esters of nitrogen mustard: cytogenetic and antineoplastic effects. Anticancer Drugs 13 (2002) 637-643
14. Kim K.H., Oudit G.Y., and Backx P.H. Erythropoietin protects against doxorubicin-induced cardiomuopathy via a phosphatidylinositol 3-kinase-dependent pathway. J. Pharmacol. Exp. Ther. 324 1 (2008) 160-169
15. Kopjar N., Želježić D., Vrdoljak A.L., Radić B., Ramić S., Milić M., Gamulin M., Pavlica V., and Fucić A. Irinotecan toxicity to human blood cells in vitro: relationship between various biomarkers. Basic Clin. Pharmacol. Toxicol. 100 6 (2007) 403-413
16. Lakovidou Z., Papageorgiou A., Demertzis M.A., Mioglou E., Mourelatos D., Kotsis A., Yadav P.N., and Kovala-Demertzi D. Platinum (II) and palladium (II) complexes with 2-acetylpyridine thiosemicarbazone: cytogenetic and antineoplastic effects. Anticancer Drugs 12 (2001) 65-70
17. Lewin, B., 2004. Genes VIII. Oxford University Press, pp. 836-837.
18. Lialiaris T., Mourelatos D., and Dozi-Vasiliades J. Enhancement and attenuation of cytogenetic damage by vitamin c in cultured human lymphocytes exposed to thiotepa or l-ethionine. Cytogenet. Cell Genet. 44 (1987) 209-214
19. Lialiaris T., Mourelatos D., and Dozi-Vassiliades J. Enhancement of cytogenetic damage by chlorpromazine in human lymphocytes treated with alkylating antineoplastics and caffeine. Mutat. Res. 206 3 (1988) 361-365
20. Lialiaris T., Mourelatos D., Boutis L., Papageorgiou A., Christianopoulou M., Papageorgiou V., and Dozi-Vassiliades J. Comparative study on cytogenetic effects by diplatinum complexes of the ligands of naphthazarine and squaric acid in human lymphocytes. J. Pharm. Exp. Ther. 251 1 (1989) 368-371
21. Lialiaris T., Mourelatos D., Stergiadou H.C., and Constantinidou H.A. Cytogenetic study for possible mutagenic activity induced by ice-nucleation bacteria or their metabolic products in human lymphocytes in vitro. Mutat. Res. 242 (1990) 163-168
22. Lialiaris T.S., Pantazaki A., Papachristou F., Lyratzopoulos E., Natsis K., and Kortsaris A.H. The mutagenic potential of vitamin C on human lymphocytes and native nucleic acids. J. Biol. Res. Thessalon. 8 (2007) 189-197
23. Lialiaris T., Lyratzopoulos E., Papachristou F., Simopoulou M., Mourelatos C., and Nikolettos N. Supplementation of melatonin protects human lymphocytes in vitro from the genotoxic activity of melphalan. Mutagenesis 23 5 (2008) 347-354
24. Lialiaris T., Kotsiou E., Pouliliou S., Kareli D., Makrinou H., Kouskoukis A., Papachristou F., and Koukourakis M. Cytoprotective activity of amifostine on cultured human lymphocytes exposed to irinotecan. Food Chem. Toxicol. 47 10 (2009) 2445-2449
25. Liao Z.B., Zhi X.G., Shi Q.H., and He Z.H. Recombinant human erythropoietin administration protects neurons from traumatic brain injuries in rats. Eur. J. Neurol. 15 (2008) 140-149
26. Marti H. Erythropoietin and the hypoxic brain. J. Exp. Biol. 207 (2004) 3233-3242
27. Mathijssen, R.H., Loos, W.J., Verweij, J., Sparreboom, A., 2002. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr. Cancer Drug 282 Targets 2, 103-123.
28. Mohyeldin A., Dalgard C., Lu H., McFate T., Tait S., Patel V., Wong K., Rushing E., Roy S., Acs G., and Verma A. Survival and invasiveness of astrocytomas promoted by erythropoietin. J. Neurosurg. 106 (2007) 338-350
29. Mpountoukas P., Vantarakis A., Sivridis E., and Lialiaris T. Cytogenetic study in cultured human lymphocytes treated with three commonly used preservatives. Food Chem. Toxicol. 46 7 (2008) 2390-2393
30. O' Leary J., and Muggia F.M. Camptothecins: a review of their development and schedules of administration. Eur. J. Cancer 34 10 (1998) 1500-1508
31. Okazaki T., Ebihara S., Asada M., Ymanda S., Niu K., and Arai H. Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 10 9 (2008) 932-939
32. Page C.P., Curtis M.J., Sutter M.C., Walker M.J.A., and Hoffman B.B. Integrated Pharmacology. third ed. (2006), Mosby Elsevier, Philadelphia pp. 518-519
33. Papachristou F., Lialiaris T., Touloupidis S., Kalaitzis C., Simopoulos C., and Sofikitis N. Evidence of increased chromosomal instability in infertile males after exposure to mitomycin C and caffeine. Asian J. Androl. 8 2 (2006) 199-204
34. Papachristou F., Simopoulou M., Touloupidis S., Tsalikidis C., Sofikitis N., and Lialiaris T. DNA damage and chromosomal aberrations in various types of male factor infertility. Fertil. Steril. 90 5 (2008) 1774-1781
35. Perry P., and Wolff S. Giemsa method for the differential staining of sister chromatids. Nature 251 (1974) 156-158
36. Ribas G., Xamena N., Creus A., and Marcos R. Sister-chromatid exchanges (SCE) induction by inhibitors of DNA topoisomerases in cultured human lymphocytes. Mutat. Res. 368 (1996) 205-211
37. Rossert J., and Eckardt K.U. Erythropoietin receptors: their role beyond eythropoiesis. Nephrol. Dial. Transplant. 20 (2005) 1025-1028
38. Sasaki R., Masuda S., and Nagao M. Erythropoietin: multiple physiological functions and regulation of biosynthesis. Biosci. Biotechnol. Biochem. 64 9 (2000) 1775-1793
39. Staker B.L., Feese M.D., Cushman M., Pommier Y., Zembower D., Stewart L., and Burgin A.B. Structure of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J. Med. Chem. 48 (2005) 2336-2345
40. Tilbrook P., and Klinken P. The erythropoietin receptor. Int. J. Biochem. Cell Biol. 31 (1999) 1001-1005
41. Tilbrook P., and Klinken P. Erythropoietin and erythropoietin receptor. Growth Factors 17 (1999) 25-35
42. Tweats D.J., Blakey D., Heflich R.H., Jacobs A., Jacobsen S.D., Morita T., Nohmi T., O'Donovan M.R., Sasaki Y.F., Sofuni T., and Tice R. Report of the IWGT working group on strategies and interpretation of regulatory in vivo tests I. Increases in micronucleated bone marrow cells in rodents that do not indicate genotoxic hazards. Mutat. Res. 627 (2007) 78-91
43. Udupa K.B. Functional significance of erythropoietin receptor on tumor cells. World J. Gastroenterol. 12 46 (2006) 7460-7462
44. Wang Z., Shen L., Tu L., Hu D., Liu G.Y., Zhou Z.I., Lin Y., Chen L.H., and Qu J. Erythropoietin protects retinal pigment epithelial cells from oxidative damage. Free Radical Biol. Med. 46 (2009) 1032-1041
45. Weiss M. New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues and clinical applications. Oncologist 8 3 (2003) 18-29
46. Wolf S., and Perry P. Differential Giemsa staining of sister chromatids and the study of sister chromatid exchange without autoradiography. Chromosomal 48 (1974) 341-353
47. Yajima N., Kurata Y., Imai E., Sawai T., and Takeshita Y. Genotoxicity of genetic recombinant human erythropoietin in a novel test system. Mutagenesis 8 3 (1993) 231-236
48. Yajima N., Kurata Y., Sawai T., and Takeshita Y. Comparative studies in induction of micronuclei by three genetically recombinant and urinary human erythropoietins. Mutagenesis 8 3 (1993) 237-241
49. Yajima N., Kurata Y., Sawai T., and Takeshita Y. Induction of micronucleated erythrocytes by recombinant human erythropoietin. Mutagenesis 8 3 (1993) 221-229
50. Yamasaki M., Mishima H., Yamashita H., Kashiwagi K., Murata K., Minamoto A., and Inaba T. Neuroprotective effects of erythropoietin on glutamate and nitric oxide toxicity in primary cultured retinal ganglion cells. Brain Res. Rev. 1050 (2005) 15-26
51. Yazihan N., Ataoǧlu H., Yener B., Aydin C., and Turk J. Erythropoietin attenuates hydrogen peroxide-induced damage of hepatocytes. Turk. J. Gastroenterol. 18 4 (2007) 239-244
52. Zhong Y., Yao H., Deng L., Cheng Y., and Zhou X. Promotion of neurite outgrowth and protective effect of erythropoietin on the retinal neurons of rats. Graefes Arch Clin. Exp. Ophthalmol. 245 (2007) 1859-1867